JTFM, in your last SA analysis, you write the following "According to Drugs.com - Prescription Drug Information hydrochlorothiazide capsules currently sell for between $12.81 and $13.12 per 30 capsule prescription. The only oral liquid form of the drug should capture at least 5% of this market. Assuming prescriptions are priced around $130, ANIP could be looking at revenues for the drug exceeding $250 million." Can you explain how you come to the 130$ prescription pricing ? I'm not well versed into the US prescription system but the tenfold price vs the 30 capsules price seems high to me (don't know if it makes sense to compare them). Thanks again for all the insights you share with us.
Market Data 
Markets 
AI
